Lake Street raised the firm’s price target on Sight Sciences (SGHT) to $7 from $5 and keeps a Buy rating on the shares after two Medicare administrative contractors finalized coverage policies for Sight Sciences’ Dry Eye Disease treatment system, TearCare. The firm sees this as “a significant positive that could be a driver of outperformance,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences Gains Medicare Pricing for TearCare
- Sight Sciences announces fee schedule establishment for TearCare procedure
- Sight Sciences to provide updated revenue guidance on Q3 earnings call
- Sight Sciences price target lowered to $4 from $4.50 at Citi
- Sight Sciences Amends Loan Agreement with Hercules